MGCD265 targets the c-MET, VEGFR1, VEGFR2, VEGFR3, Tie-2 and Ron receptor tyrosine kinases, which appear to play key roles in tumor development and survival, blood vessel formation (angiogenesis) and cancer cell metastasis.
Donald Corcoran, president and CEO of MethylGene, said: “MGCD265 has the potential to be clinically tested in a number of solid tumor types. This compound, along with MGCD0103, our HDAC inhibitor, provides MethylGene with a pipeline of compounds in areas of significant scientific and industry interest.”